Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ANDRODERM vs ISOVUE-200
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Testosterone is an androgen receptor agonist; it binds to androgen receptors, leading to changes in gene expression that promote male secondary sexual characteristics and maintain libido, muscle mass, and bone density.
Iodinated contrast medium that attenuates X-rays, providing radiographic contrast by increasing the density of blood vessels and tissues.
FDA-approved: testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone (hypogonadism). Off-label: delayed puberty in males, female-to-male transgender hormone therapy.
Intrathecal administration for myelography (lumbar, thoracic, cervical, and total columnar myelography),Intravascular administration for angiocardiography, aortography, peripheral arteriography, venography, and contrast-enhanced computed tomography (CT),Body cavity imaging: arthrography, hysterosalpingography, and fistulography
Apply one 2.5 mg or 5 mg transdermal system to clean, dry, intact skin on the abdomen, upper arms, or thighs once daily, preferably in the morning. Starting dose is 5 mg daily; adjust based on serum testosterone levels.
Intravenous administration of 1.0-2.0 m L/kg (200 mg iodine/m L) for computed tomography; intra-arterial doses vary by procedure, typically 5-80 m L total. Maximum recommended dose: 2.0 m L/kg.
Terminal elimination half-life is approximately 10–100 minutes (rapid), but due to transdermal absorption, effective half-life is extended to about 8–10 hours after patch application.
2 hours in normal renal function; prolongs up to 30 hours in severe renal impairment. Closely correlates with creatinine clearance.
Testosterone is metabolized primarily in the liver via CYP3A4 and CYP2C9 isoenzymes, as well as by 5α-reductase to dihydrotestosterone (DHT) and by aromatase to estradiol.
Iopamidol is not metabolized; eliminated unchanged via glomerular filtration.
Approximately 90% of testosterone metabolites are excreted in urine as glucuronide and sulfate conjugates; 6% are excreted in feces via bile.
Renal: 100% unchanged as iohexol; glomerular filtration with no tubular reabsorption. No biliary/fecal elimination.
Approximately 98–99% bound: primarily to sex hormone-binding globulin (SHBG, ~40%) and albumin (~60%).
<2% bound; negligible binding to plasma proteins.
Volume of distribution is approximately 0.2–0.8 L/kg, reflecting distribution into steroid-sensitive tissues and binding proteins.
0.24 L/kg; restricted to extracellular fluid, no intracellular penetration.
Transdermal bioavailability is approximately 10–15% of the nominal dose (based on 24-hour application), with interindividual variability due to skin permeability.
Oral: 0% (not absorbed); IV/IA/Intrathecal: 100% (administered directly into blood/CSF).
No specific dose adjustment recommended for renal impairment. Use with caution in patients with severe renal impairment due to potential fluid retention.
e GFR <30 m L/min/1.73m²: Administer with caution, consider prophylaxis with hydration and N-acetylcysteine. e GFR <15: Use only if diagnostic benefit outweighs risk of contrast-induced nephropathy. No specific dose reduction established; consider using lowest feasible volume.
Contraindicated in patients with severe hepatic impairment (Child-Pugh class C). In mild to moderate impairment (Child-Pugh A or B), use with caution and monitor liver function; no specific dose adjustment guidelines.
No specific adjustments recommended for Child-Pugh class A, B, or C. Monitor renal function in patients with severe liver disease due to risk of hepatorenal syndrome.
Not indicated for use in pediatric patients. Safety and efficacy have not been established in children <18 years.
Neonates and infants: 1.5-2.0 m L/kg intravenously. Children: 1.0-2.0 m L/kg intravenously; maximum 2.0 m L/kg. For intra-arterial use, consult weight-based dosing guidelines.
Initiate at 2.5 mg once daily in elderly patients due to increased risk of adverse effects, particularly prostatic hyperplasia and cardiovascular events. Monitor serum testosterone levels and adjust as needed.
No specific dose adjustment required based on age alone. Assess renal function (e GFR) in elderly patients as age-related decline is common; follow renal adjustment guidelines. Ensure adequate hydration before and after administration.
WARNING: Cardiovascular risk - Increased risk of myocardial infarction, stroke, and cardiovascular death has been reported with testosterone replacement therapy. Only use in men with confirmed hypogonadism.
Not for intrathecal use with ISOVUE-200 (iopamidol injection 41%) due to risk of severe adverse reactions including seizures, paralysis, and death.
Elderly patients and those with known cardiovascular risk factors should be monitored for cardiovascular events.,May exacerbate sleep apnea in predisposed individuals.,Can cause erythrocytosis; monitor hematocrit.,May accelerate growth of prostate cancer and benign prostatic hyperplasia; monitor prostate-specific antigen (PSA).,Monitor for signs of virilization in women if used off-label.,Possible hypercalcemia in immobilized patients.
Risk of severe hypersensitivity reactions including anaphylaxis; acute kidney injury in patients with pre-existing renal impairment; CNS adverse effects including seizures with intrathecal administration; thyroid dysfunction in patients with hyperthyroidism; contrast-induced nephropathy.
Men with carcinoma of the breast or known or suspected carcinoma of the prostate.,Women who are pregnant or may become pregnant (risk of virilization of fetus).,Hypersensitivity to testosterone or any component of the product.,Severe renal or hepatic impairment (risk of fluid retention).
Absolute: Hypersensitivity to iopamidol or any component; history of severe adverse reaction to iodinated contrast media; anuria or severe renal impairment (for intravascular use).,Relative: Pregnancy (only if clearly needed); lactation; multiple myeloma; pheochromocytoma; sickle cell disease.
No known food interactions. Take with or without food.
No specific food interactions with ISOVUE-200. Patients are generally encouraged to hydrate with clear fluids before and after the procedure. There are no dietary restrictions. However, in patients with diabetes taking metformin, metformin should be withheld for 48 hours after contrast administration and only resumed after renal function is re-evaluated.
Androderm (testosterone) is contraindicated in pregnancy due to virilization of female fetus. First trimester: high risk of pseudohermaphroditism in female fetuses (labial fusion, clitoromegaly) with androgen exposure during critical period of genital differentiation (weeks 8-12). Second and third trimesters: risk of clitoral enlargement, advanced bone age, and potential long-term behavioral effects. Male fetuses may experience premature sexual development. No adequate studies; USP pregnancy category X.
Iodinated contrast agents cross the placenta but have not been associated with teratogenic effects in humans. First trimester: theoretical risk from free iodide; avoid unless essential. Second and third trimesters: no known teratogenicity; neonatal thyroid function monitoring recommended after exposure.
Testosterone is excreted into human milk; M/P ratio not established. Potential for virilization of female infants and early puberty in male infants. Risk of suppression of maternal lactation (androgen-induced decrease in prolactin). Contraindicated during breastfeeding; alternative therapies recommended.
Minimal excretion into breast milk; M/P ratio not established. Iodinated contrast is poorly absorbed orally and poses negligible risk to nursing infant. Interruption of breastfeeding not required.
Androderm is contraindicated in pregnancy; no dose adjustments applicable. If therapy is necessary for maternal hypogonadism, discontinue immediately upon pregnancy recognition. Pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) are irrelevant due to contraindication. Do not dose in pregnancy.
No dose adjustment required in pregnancy; use lowest diagnostic dose. Monitor for volume overload in preeclampsia or compromised cardiac function.
Apply to clean, dry, intact skin on the abdomen, thighs, upper arms, or back. Rotate application sites to minimize skin reactions. Do not apply to genitals or scrotum. Avoid showering or swimming for at least 3-4 hours after application to ensure absorption. Monitor serum testosterone levels 14 days after starting therapy or dose adjustment, drawn in the morning before application. Use with caution in patients with known or suspected prostate cancer or breast cancer. Warn patients about the risk of transfer to women and children through skin contact; cover application site with clothing or wash skin before contact.
ISOVUE-200 (iopamidol 41%) is a nonionic, low-osmolality iodinated contrast medium. It is indicated for intrathecal administration in myelography (lumbar, thoracic, cervical, total columnar) and for contrast enhancement in CT and angiocardiography. Key pearls: (1) Monitor renal function before administration due to risk of contrast-induced nephropathy; (2) Prehydrate patients with normal saline to reduce nephrotoxicity; (3) Have emergency equipment available for hypersensitivity reactions; (4) Avoid in patients with known iodine allergy or prior reaction to contrast; (5) Do not mix with other medications in the same syringe; (6) For intrathecal use, ensure proper patient positioning to minimize cephalad flow; (7) Use with caution in patients with sickle cell disease, pheochromocytoma, or hyperthyroidism.
Apply the gel to clean, dry, intact skin once daily in the morning.,Rotate application sites to prevent skin irritation.,Avoid direct skin contact with women and children; wash hands thoroughly after application and cover the site with clothing.,Do not apply to the genitals or scrotum.,Do not shower or swim for at least 3-4 hours after application.,Monitor for signs of skin irritation, such as redness or itching.,Report any swelling of the ankles, difficulty breathing, or changes in mood or sleep.,Keep the medication away from children and pets.
Inform your doctor if you have ever had an allergic reaction to iodine, contrast dye, or any medications.,Tell your healthcare provider if you have kidney disease, diabetes, asthma, heart disease, or thyroid problems.,You may need to stop taking certain medications (e.g., metformin) before the procedure; follow your doctor's instructions.,You will be asked to drink plenty of fluids before and after the procedure to protect your kidneys.,During injection, you may feel warmth, a metallic taste in the mouth, or nausea; these are usually temporary.,Report any severe symptoms such as difficulty breathing, hives, swelling, or chest pain immediately.,After the procedure, you may resume normal diet unless otherwise instructed.,Breastfeeding women should pump and discard breast milk for 24 hours after contrast administration.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ANDRODERM vs ISOVUE-200, answered by our medical review team.
ANDRODERM is a Androgen that works by Testosterone is an androgen receptor agonist; it binds to androgen receptors, leading to changes in gene expression that promote male secondary sexual characteristics and maintain libido, muscle mass, and bone density.. ISOVUE-200 is a Contrast Media that works by Iodinated contrast medium that attenuates X-rays, providing radiographic contrast by increasing the density of blood vessels and tissues.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ANDRODERM and ISOVUE-200 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ANDRODERM is: Apply one 2.5 mg or 5 mg transdermal system to clean, dry, intact skin on the abdomen, upper arms, or thighs once daily, preferably in the morning. Starting dose is 5 mg daily; adjust based on serum testosterone levels.. The standard adult dose of ISOVUE-200 is: Intravenous administration of 1.0-2.0 m L/kg (200 mg iodine/m L) for computed tomography; intra-arterial doses vary by procedure, typically 5-80 m L total. Maximum recommended dose: 2.0 m L/kg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ANDRODERM and ISOVUE-200 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ANDRODERM is classified as Category C. Androderm (testosterone) is contraindicated in pregnancy due to virilization of female fetus. First trimester: high risk of pseudohermaphroditism in female fetuses (labial fusion, . ISOVUE-200 is classified as Category C. Iodinated contrast agents cross the placenta but have not been associated with teratogenic effects in humans. First trimester: theoretical risk from free iodide; avoid unless essen. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.